Cells possess within their epigenetic repertoire the ability to undergo the active process of cellular suicide, apoptosis (programmed cell death). This represents the physiologically relevant mode of cell death that proceeds via an energy-dependent cascade of biochemical and morphological changes, resulting in the death and elimination of the cell. In the normal prostate epithelium, the rate of cell proliferation is balanced by an equal rate of cell death, so that neither involution nor overgrowth of the gland occurs.
Cells possess within their epigenetic repertoire the ability to undergo the active process of cellular suicide, apoptosis (programmed cell death). This represents the physiologically relevant mode of cell death that proceeds via an energy-dependent cascade of biochemical and morphological changes, resulting in the death and elimination of the cell. In the normal prostate epithelium, the rate of cell proliferation is balanced by an equal rate of cell death, so that neither involution nor overgrowth of the gland occurs.
Transforming growth factor-b (TGF-b) plays a signi®-cant role in the negative regulation of prostate growth due to its ability to inhibit cell proliferation and induce apoptosis. Recent studies from our laboratory have demonstrated a signi®cant downregulation in the expression of TGF-b receptors R-1 and R-II in human prostate cancer and a correlation of this receptor loss with tumour progression. Gene transfer-mediated overexpression of TGF-b R-II receptor in the human prostate cancer cells LNCaP which are resistant to the negative growth effects of TGF-b due to the loss of R-II receptor, restored TGF-b sensitivity and signalling, lead to suppression of the tumourigenic behaviour of these cells both in vitro and in vivo. This suppression of prostate tumourigenicity was due to a dual action of TGF-b:
inhibition of cell proliferation of the R-II overexpressing prostate cancer cells by arresting cell cycle progression in G1 due to a transient increase in the cyclindependent kinase inhibitors p21 and p27
Kip1 ; a simultaneous induction of apoptosis via a caspase-1 mediated pathway.
Evidence gathered in our laboratory linking these key cell cycle regulator molecules to the TGF-b-mediated apoptotic death process in prostate cancer cells will be discussed. Furthermore, a recent analysis of caspase expression in human prostatic tumours revealed a signi®cant reduction of caspase levels correlating with prostate cancer progression.
In summary, our ®ndings support a role for the TGF-b R-II receptor as a potential tumour suppressor gene in prostate tumourigenesis, exerting its negative growth effect via a dual control on cell proliferation and apoptosis. In addition, they provide the ®rst evidence to implicate activation of the caspase cascade in the signalling pathway of TGF-b-mediated apoptosis in prostate cancer cells.
